Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer
about
Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineVincristine-induced peripheral neuropathy in pediatric cancer patientsLong term side effects of adjuvant chemotherapy in patients with early breast cancerChemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience.Association between treatment toxicity and outcomes in oncology clinical trialsOverview of neuropathy associated with taxanes for the treatment of metastatic breast cancer.Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy.Neurotoxic 1-deoxysphingolipids and paclitaxel-induced peripheral neuropathyA nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities.Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199.CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxelCYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity.Challenges of guarantee-time biasImpact of obesity on cancer survivorship and the potential relevance of race and ethnicity.Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity.Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review.Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African Americans.Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives.Incidence of taxane-induced peripheral neuropathy receiving treatment and prescription patterns in patients with breast cancer.BMI, Lifestyle Factors and Taxane-Induced Neuropathy in Breast Cancer Patients: The Pathways Study.Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials.Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall riskThe early onset of peripheral neuropathy might be a robust predictor for time to treatment failure in patients with metastatic breast cancer receiving chemotherapy containing paclitaxel.The impact of diabetes on neuropathic symptoms and receipt of chemotherapy among colorectal cancer patients: results from the PROFILES registry.Taxane-Induced Peripheral Neurotoxicity.Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30.Estrogen receptor-α promoter methylation is a biomarker for outcome prediction of cisplatin resistance in triple-negative breast cancer.Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort.Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715).Risk of docetaxel-induced peripheral neuropathy among 1,725 Danish patients with early stage breast cancer.The evaluation of changes in peripheral neuropathy and quality-of-life using low-frequency electrostimulation in patients treated with chemotherapy for breast cancer: a study protocolDocetaxel-induced neuropathy: A pharmacogenetic case-control study of 150 women with early-stage breast cancer
P2860
Q26853619-7BF8BB57-E239-49CE-92EC-0DC50DDCE527Q28078232-B5FB743A-7BF6-4B2F-8E5B-8A2FCA55DB92Q28083233-F6E0325B-CFA1-419A-ACC6-7B9FEB83C39EQ33984071-B74CCFA2-E638-48EF-959D-84BBF01AEBD9Q34395352-CB2BAC03-E2B8-4D41-8FCF-34F1993769BBQ34458581-0DCCA4D8-94C8-4F07-B8A1-F83E699D5D71Q34633385-DBBCC062-571E-440C-BBAB-AB6136B121E1Q36171312-9A6E47F1-A55C-4AA7-B14D-AACF13CD5D38Q36409909-5A1BE244-6B6B-4893-B19E-896A62F56B86Q36475847-6CD050ED-2BCA-47AD-8E12-178C95232B26Q36862832-6FE0F896-C299-435C-AE74-E2151B5C06DDQ36940993-5A3E78C3-1054-4B92-8A1F-6FE43EE417F6Q37066734-A3317AC9-C67D-4236-BAE5-6C86A08567B2Q37180380-1D15E184-E3F2-47B9-95B9-ACE192F71857Q37233810-E77C80DF-3A34-4D77-9446-C996CF8011D4Q37662576-93DE82CE-9F40-40B6-9E92-4E517142A559Q37696110-9379AF4C-60BB-4229-AE3F-D069CB3ACE51Q38370562-0C01A4FA-DF77-45CE-864D-1E4C4F0B3A60Q39138091-2A67F58C-8D7D-462A-B488-79ACB2A41777Q39236303-23AB4EF0-4DA0-4DBF-AFD6-8E7EDA4C7249Q39668102-32F1EA66-8ADF-47F1-B9DF-4A6DD48857BDQ41009010-81D56928-B8FC-4D0E-AD39-321CE3708500Q41227394-BD02E1DF-5A2A-46AC-A4CC-3F972036A154Q41499485-E401FA53-7257-4B37-990C-135B24E4AA74Q45759415-C7FD5674-0A61-48F7-A821-036DEA8C73ADQ46606896-E471ED86-761A-4D2F-8CFC-7E63CEAEEA78Q49875019-9E6F9B81-4E94-4DE2-B362-5EDEA8F3B932Q50035155-F346022A-50A4-4DA3-8CA8-5B9560242CEAQ50089791-CD9B5EA1-6D62-44A0-B334-349A5CB4D5C6Q50560002-CE912DC2-8A6F-4630-8F66-639DDC1CA18FQ57212709-EC234DFE-EAC9-44EF-B602-1C7CEACB367BQ57581249-BFC7B73A-2E41-490D-8831-45E1D6AA08A1
P2860
Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 July 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Neuropathy is not associated w ...... apy for operable breast cancer
@en
Neuropathy is not associated w ...... py for operable breast cancer.
@nl
type
label
Neuropathy is not associated w ...... apy for operable breast cancer
@en
Neuropathy is not associated w ...... py for operable breast cancer.
@nl
prefLabel
Neuropathy is not associated w ...... apy for operable breast cancer
@en
Neuropathy is not associated w ...... py for operable breast cancer.
@nl
P2093
P2860
P356
P1476
Neuropathy is not associated w ...... apy for operable breast cancer
@en
P2093
Bryan P Schneider
Edith A Perez
Fengmin Zhao
George W Sledge
Joseph A Sparano
Molin Wang
Nancy E Davidson
Silvana Martino
Tom Saphner
Vicky Jones
P2860
P304
P356
10.1200/JCO.2011.39.8446
P407
P577
2012-07-30T00:00:00Z